A case report of a high-grade pancreatic NET patient with high tumor mutation burden who benefited from chemotherapy combined with immunotherapy

#3969

Introduction: For patients with well-differentiated G3 NET, the efficacy of immune checkpoint inhibitors (ICIs) is currently not clear. The expression level of PD-L1 in tumor tissue, high microsatellite instability (MSI-H), and high tumor mutational burden (TMB-H) are considered indicators for selecting potential beneficiaries of immunotherapy.

Aim(s): We report a patient with G3 grade pancreatic NET who showed TMB-H after 2 rounds of CAPTEM and benefited from second-line chemotherapy combined with immunotherapy.

Materials and methods: Clinical case.

Conference:

Presenting Author:

Authors: Jia X, Liang Y, Chen J,

Keywords: g3 pancreatic net, captem, tmb-h, icis,